Latest / CME Outfitters Medical Education / Riding the Waves of Obesity Science – The Phenotype Breakers: Heterogeneity, Signals, and Who Might Benefit from Which Biology
Transcript
- 0:11SPEAKER_00: Hello, I'm Dr.
- 0:12SPEAKER_00: Robert Krishner.
- 0:13SPEAKER_00: I'd like to welcome you to Riding the Waves of Obesity Science.
- 0:17SPEAKER_00: This is Snack number three of four, and it's titled The Phenotype Breakers, Heterogeneity, Signals, and Who Might Benefit from Which Biology.
- 0:28SPEAKER_00: This activity is provided by CME Outfitters and is supported by an independent educational grant from Novonorisk, Incorporated.
- 0:36SPEAKER_00: Hi, I'm Dr.
- 0:37SPEAKER_00: Rabu Krishner.
- 0:38SPEAKER_00: I'm Professor Emeritus at Northwestern University Feinberg School of Medicine in the Departments of Medicine and Medical Education in Chicago.
- 0:47SPEAKER_00: I'm very pleased to welcome Dr.
- 0:49SPEAKER_00: Andreas Ocosta of the Mayo Clinic, who I will ask to introduce himself.
- 0:54SPEAKER_00: Welcome, Dr.
- 0:55SPEAKER_00: Ocosta.
- 0:58SPEAKER_01: Thank you, Dr.
- 0:58SPEAKER_01: Kushner.
- 0:59SPEAKER_01: It's a pleasure to be here to explore this important topic and chatting with you.
- 1:03SPEAKER_01: I'm Andres Acosta.
- 1:04SPEAKER_01: I'm a professor of medicine, the Lanny Family Director for the Nutrition Obesity Research Program at Mayo Clinic, also director of the Precision Medicine for Obesity Program.
- 1:13SPEAKER_01: I'm consultant in gastroenterology and hepatology, and I'm board certified in internal medicine, gastroenterology, and obesity.
- 1:20SPEAKER_01: And I'm delighted to be talking to you today about the heterogeneity of obesity and weight loss response.
- 1:25SPEAKER_00: Triple boarded.
- 1:27SPEAKER_00: I love that.
- 1:28SPEAKER_00: You know, I've been looking forward to this so much.
- 1:31SPEAKER_00: Clinicians have been using phenotypes for quite some time now, but it's usually used looking at characteristics like distribution of body fat, the high-risk phenotype.
- 1:42SPEAKER_00: Some of us, including me, use behavioral and cognitive phenotypes.
- 1:47SPEAKER_00: You're really breaking new ground, which is what we're going to be talking about today.
- 1:50SPEAKER_00: And as phenotypes as it relates to response to therapy.
- 1:53SPEAKER_00: So let me start off with how you think about phenotypes or how do you define it and kind of do a segue into how your phenotypes are really heading in a completely new and exciting direction.
- 2:06SPEAKER_01: Yeah, absolutely.
- 2:06SPEAKER_01: Thank you, Dr.
- 2:07SPEAKER_01: Kush.
- 2:07SPEAKER_01: And I think that's something that for us who start working on obesity, we've been talking about phenotypes of obesity from different perspectives.
- 2:17SPEAKER_01: So let's start by saying, you know, what is a phenotype?
- 2:20SPEAKER_01: A phenotype is simple the interaction between our genetics and our environment.
- 2:27SPEAKER_01: The genetics, that footprint that we come with, our environment is what we're exposed through life, and then it tells us who we are, right?
- 2:35SPEAKER_01: So uh that so it's very easy to then try to explain different characteristics in biology, in our human body, described by phenotypes.
- 2:44SPEAKER_01: And as you said, one of the most well-known phenotypes, many people talk about our adipose distribution, apples versus pears, right?
- 2:52SPEAKER_01: Where do we accumulate our fat?
- 2:53SPEAKER_01: Is it in our belly or more in our hips?
- 2:56SPEAKER_01: We know that belly fat, abdominal fat, or abdominal word circumference is actually worse for you overall, but both of them are bad, right?
- 3:04SPEAKER_01: So that is one type of phenotype.
- 3:06SPEAKER_01: That type of phenotype is more where we just put our disposition or our fat where it is distributed.
- 3:13SPEAKER_01: So it's a distribution of body fat.
- 3:15SPEAKER_01: There's other types of phenotypes that I've been talking throughout, and all of them are equally important because all of this tell us something about our disease of obesity, where we are on the obesity journey.
- 3:27SPEAKER_01: Another very important phenotype that people have been talking about is whether you are metabolically healthy or metabolically unhealthy.
- 3:34SPEAKER_01: So why this matters?
- 3:35SPEAKER_01: Because we have obesity, we have the excess of body weight, whether we put that fat in our abdomen or in our hips, that doesn't matter.
- 3:43SPEAKER_01: Some people will develop early, metabolically unhealthy, higher likelihood of developing insulin resistance, pre-diabetes, then diabetes, and that increases our risk of heart disease.
- 3:54SPEAKER_01: Some other people are a little more, you know, more takes them a little bit longer time to develop that metabolically unhealthy or are protective as well against that metabolically unhealthy.
- 4:05SPEAKER_01: It's a minority of patients who actually have this metabolically healthy through their lifespan.
- 4:11SPEAKER_01: But it's still an important phenotype to address.
- 4:14SPEAKER_01: You have been telling us about this behavioral phenotypes, whether where you are in your behavioral phenotype, there's other types of classifications, such as the three-factor eating domains, which tells about these phenotypes on the eating behavior.
- 4:27SPEAKER_01: And what we decided to do is we said, well, okay, we've learned a lot about behavior, we've learned a lot about fat distribution and the risk for insulin resistance.
- 4:38SPEAKER_01: But what happens with our appetite regulation when we measure this from a perspective, when we measure our gut brain access, and these three clear components in our appetite regulation, which is hunger, satiation, how many calories I consume to feel full, so satiation, and then our prosprandial satiety.
- 5:00SPEAKER_01: So these are three clear points that we in you know appetite regulation studies have been talking for many decades.
- 5:08SPEAKER_01: And then on the other side of the equation, we have our energy expenditure.
- 5:12SPEAKER_01: And the end expenditure can also be subclassified in our basal or resting energy expenditure, where we burn when we are at rest, you know, or our cells are active all the time, so we're burning calories just by sitting without moving.
- 5:25SPEAKER_01: But then we have our physical activity, which can be divided in the exercise-related physical activity or non-exercise related physical activity.
- 5:34SPEAKER_01: And finally, we burn some calories when we do things like digestion, so then the postprineal energy expenditure.
- 5:41SPEAKER_01: So these two sides of the equation matter a lot because they tell us and they control our energy balance and our energy homeostasis.
- 5:51SPEAKER_01: So what we decided to do is study all these variables in about 500 patients, and about a little bit over a decade ago in 2015, we came up with the first observation that many of these biological traits, hunger, satiation, prospennous satiety, rest energy expenditure, as well as our non-exercise physical activity, are different if we're lean or normal weight versus we have a BMI greater than 30.
- 6:19SPEAKER_01: But the matter of the fact is that we're extremely different.
- 6:22SPEAKER_01: And what we realize from that publication is that it's extremely heterogeneous.
- 6:27SPEAKER_01: There's people who have very high levels of hunger, there's people who have very low levels of prosperous satiety, there's people who want to consume a lot of calories in one meal, there's people who want to munch through the day.
- 6:36SPEAKER_01: And it's only a matter that we talk with 10 different people, 10 different patients, or 10 different friends, and we will see these different ways of how we consume calories.
- 6:44SPEAKER_01: And same thing with our expenditure.
- 6:46SPEAKER_01: So back then we did the first classification with 11 that came up with 11 types of these energy balance phenotypes.
- 6:55SPEAKER_01: And then we kind of simplify it into four groups that explain about 85% of the variability of the energy balance phenotypes.
- 7:05SPEAKER_01: So these energy balanced phenotypes, as I like to call them, have a cause of a component of behavioral because we couldn't really leave aside the anxiety and the stress-eating behavior.
- 7:17SPEAKER_01: Those others can continue to be part of it.
- 7:19SPEAKER_00: So let me ask you, Andreas, you talked about the different uh, you know, um phenotypes regarding intake and appetite and satiety.
- 7:26SPEAKER_00: Where does reward-based eating come in?
- 7:29SPEAKER_00: Do you consider that as part of the appetite or the you know the uh satiety phenotypes?
- 7:36SPEAKER_01: Yeah.
- 7:36SPEAKER_01: So when we talk about eating behavior, you know, science has been describing these in two different characteristics.
- 7:44SPEAKER_01: One is our homeostatic eating behavior that we and all um mammals have, and then on top of that, we have our hedonic eating behavior, which comes on top of our homeostatic eating behavior.
- 7:56SPEAKER_01: So that concept that we talk all the time, that even though you just have a big meal, you still have room for dessert, is when your hedonic eating behavior, the reward, overcomes your homeostatic sickness.
- 8:08SPEAKER_01: But most of our eating, but not in everyone, so we have to avoid saying things in absolute.
- 8:14SPEAKER_01: A lot of us have our eating patterns are regulated by our homeostatic eating behavior, but they can be overcome or you know um uh or you know, overpassed by our hedonic eating behavior.
- 8:27SPEAKER_01: But not everyone has a problem with obesity with our hedonic eating behavior.
- 8:32SPEAKER_01: So it's clear that there's people who have a problem with reward and they look for seek for food for seeking for the coping up with life, like we do for alcohol or smoking or things like that, but not everyone.
- 8:45SPEAKER_01: So it's an important component, but doesn't explain the whole picture.
- 8:49SPEAKER_01: And that's why we need to go back to understanding and separating the homeostatic or so the hedonic killing behavior.
- 8:55SPEAKER_00: So those are the types of phenotypes I think that a lot of clinicians identify with.
- 8:59SPEAKER_00: Not every patient has this enticement of food, and others do.
- 9:03SPEAKER_00: Uh no.
- 9:03SPEAKER_00: So, Andreas, you see, you laid out you went from, I think you said 10 phenotypes and down to four.
- 9:10SPEAKER_00: Tell us what those four phenotypes are that you settled on that took care of most of the variants.
- 9:17SPEAKER_00: Yeah.
- 9:18SPEAKER_01: So so we came down to these four, which explain about 85% of the variants.
- 9:23SPEAKER_01: And these four phenotypes are um are the following.
- 9:27SPEAKER_01: The first one, high calories to satiation, so high calories consumed to feel fullness.
- 9:33SPEAKER_01: And to explain this to my patients, I call this the hunger brain phenotype.
- 9:38SPEAKER_01: So we have a server of studies, uh, one of them published last year in Cell Metabolism, showing that these individuals have a lot of genetic mutations and variants in the um in the more hypothalamic area that are controlling appetite and uh also on the brainstem, and these patients do not know when to stop eating.
- 9:57SPEAKER_01: So they start eating, they go for seconds and thirds.
- 10:00SPEAKER_01: So that's why I call it they have high calories to satiation, and the colloquial name that I use with my patients is hungry brain.
- 10:08SPEAKER_01: Now, the next group is hungry gut, or the term is abnormal prosprandial satiety.
- 10:15SPEAKER_01: That's the scientific term.
- 10:16SPEAKER_01: But in literature, we always get confused this term satiation versus satiety.
- 10:22SPEAKER_01: It's difficult to separate them.
- 10:23SPEAKER_01: Sometimes we say I ate to satiety or I'm eating to satiety.
- 10:27SPEAKER_01: The reality is we're eating to satiation, and that satiety effect is a prosprandial satiety that lasts for a period of time.
- 10:35SPEAKER_01: So we measure prosperial satiety on time.
- 10:38SPEAKER_01: And people with abnormal prosperial satiety, their phenotype is that they feel hungry in between meals, that increased hunger in between meals comes with a rapid gastric empty, and a group of patients and the publication is already on preprint and is coming out in the next month, have very low levels of GOP1, while other group of people, despite feeling hungry between meals and rapid gastric empty, they have high levels of GOP1.
- 11:06SPEAKER_01: So we think the problem of these individuals is on the gut.
- 11:10SPEAKER_01: Either the GOP1 is not having an effective signal, that would be a more like a type 2 hungry gut, and or a group of people have a their cells, their enterendoctrin cells are not making enough GOP1, they have a type 1 hungry gut phenotype.
- 11:26SPEAKER_00: So clinically, these would be folks, I guess, would say, I I'm I snack more frequently, that I get hungry, I'm not satisfied in between meals.
- 11:35SPEAKER_00: So clinically, that I presume that's what you're listening for.
- 11:38SPEAKER_01: Absolutely.
- 11:39SPEAKER_01: Okay.
- 11:40SPEAKER_01: It's very common to see to hear from patients.
- 11:43SPEAKER_01: I just had a normal meal and within an hour or two, I feel hungry again.
- 11:47SPEAKER_01: So that's that's hungry gut.
- 11:48SPEAKER_01: Okay.
- 11:48SPEAKER_01: That's hungry gut.
- 11:50SPEAKER_01: The third group is those people who are eating for reward, the hedonic eating behavior, emotional eating.
- 11:56SPEAKER_01: Uh, you ask them different questionnaires and they have the three-factor eating domain, they have uh elevated uh the emotional eating domain.
- 12:04SPEAKER_01: If you ask them, do you eat when you feel anxious, they say yes.
- 12:07SPEAKER_01: Do you eat when you're under stress, they say yes.
- 12:09SPEAKER_01: You know, I'm preparing for this your conversation with you, I'm a little bit anxious, I'm gonna have a piece of chocolate, and so on.
- 12:14SPEAKER_01: Very clear reward-eating behavior, right?
- 12:18SPEAKER_01: And reward can be good or bad.
- 12:21SPEAKER_01: I have a patient that I like to joke that that share that told me one day, Doc, my problem is that when I have a bad day, I have to drive through danking donuts.
- 12:31SPEAKER_01: And when I have a good day, I need to drive through dunking donuts, right?
- 12:34SPEAKER_01: So clearly food helps them cope with the good and bads of life.
- 12:37SPEAKER_01: Right, right, right.
- 12:38SPEAKER_01: And the last group is patients who have an abnormal metabolism, the resting energy expenditure is lower than predicted.
- 12:47SPEAKER_01: And that this can be measured by multiple different ways.
- 12:50SPEAKER_01: But whether you calculate this by equations such as the Harris Benedict, which calculate your uh energy expenditure by your age and your uh gender and your height, or by other things, by other equations using your body composition, like your fat mass and your fat-free mass, these individuals are just burning lower than they should be predicted.
- 13:10SPEAKER_01: So you measure it, and they are lower than what should be predicted, about 10% lower than predicted, and you look at them further, and they have low mass of mass.
- 13:21SPEAKER_01: So they have this equivalent, some people like to call this sarcopenic obesity.
- 13:25SPEAKER_01: They have a higher percentage of fat mass compared to their fat-free mass, and they're not burning enough calories.
- 13:32SPEAKER_01: So these are the key four groups that explain the variability, the larger variability on these energy balance phenotypes.
- 13:39SPEAKER_00: So, phenotypes, before we move on to some other stuff, Andreas, phenotypes are are a nice neat package for us to think about clinically.
- 13:48SPEAKER_00: But my guess is there's overlap because a lot of these are states, they're not traits, they overlap, they may or may not change with time, at least some phenotypes uh do.
- 13:57SPEAKER_00: So, how many of the of the individuals or patients you've seen really have overlapping phenotypes?
- 14:04SPEAKER_00: Where I guess you're talking about the predominant one, is what you've been describing?
- 14:08SPEAKER_01: Yeah, absolutely.
- 14:09SPEAKER_01: So, Kush, we have been looking at this in multiple studies.
- 14:12SPEAKER_01: Uh so when we look at 500 patients initially, we saw that 27% of patients have two or more phenotypes.
- 14:21SPEAKER_01: Three or more is only about 10%, and it's less than 1% of people who have all four phenotypes.
- 14:27SPEAKER_01: But it's it's important to say at least a third of our patients will have two or more phenotypes.
- 14:32SPEAKER_01: So, exactly as you said, what do we do then if we're measuring these phenotypes in our practice or we're talking with our patients and we realize that this patient might have a couple of similar phenotypes or more than one phenotype?
- 14:45SPEAKER_01: We try to identify what is the most predominant phenotype.
- 14:48SPEAKER_01: But if we're also going to suggest an intervention, we also try to figure out what is the most successful intervention for what phenotype, and then try to use that intervention and then select the other other interventions for the other phenotypes.
- 15:00SPEAKER_00: So the art of medicine.
- 15:02SPEAKER_00: Yeah, exactly.
- 15:03SPEAKER_00: That makes sense.
- 15:04SPEAKER_00: Before we move on to, I think the most exciting area of phenotypes, and that is response to therapy.
- 15:09SPEAKER_00: I do want to go back to just the clinician one more time.
- 15:13SPEAKER_00: You identified a lot of these phenotypes by doing procedures or measurements that are not commonly done in the clinic, like resting metabolic rate, gastric emptying, and ad libitum meal, uh, questionnaires and instruments we don't typically use in that.
- 15:29SPEAKER_00: So have you have you developed methods of identification that are more practical for the clinician without having to do these more scientific laboratory type of assessments?
- 15:41SPEAKER_01: Yeah.
- 15:43SPEAKER_01: So absolutely.
- 15:44SPEAKER_01: So what we have, so we thought was important when we started working on this NIH-sponsor research uh, you know, almost 15 years ago, was essential to outline what is the gold standard to measure these energy traits or energy balance traits, and then being able to simplify it for the physician, for the BC clinician.
- 16:06SPEAKER_01: So it's important to go to that level of right rigor to actually explain this variability on obesity, and then go to find biomarkers that can help us explain.
- 16:18SPEAKER_01: So, as you said, measuring these energy balance phenotypes takes about 10 hours at the Mayo Clinic.
- 16:24SPEAKER_01: There's multiple different academic settings around the world where we're doing the whole full 10-hour phenotype, but it's a very complicated thing.
- 16:32SPEAKER_01: It starts with measuring energy expenditure, rest energy expenditure by individual calorimetry, then the body composition either with an MRI or a DEXA scan, then doing gastric empty test and simultaneously collect blood for hormones and do visual analog scales, do questionnaires in the morning to understand the uh the eating behavior and the hedonic eating behavior as well as the physical activity of the patients, then doing a deliberal meal at the lunchtime, ask patients to eat as much as they can.
- 17:03SPEAKER_01: We use stuffers asagna, other groups have been using pizza, rice balls, and things like that.
- 17:08SPEAKER_01: And then follow these patients for another two hours to understand their visual analysis scales of appetite and satiety.
- 17:15SPEAKER_01: So 10 hours.
- 17:17SPEAKER_00: No, not a typical clinic day.
- 17:19SPEAKER_00: So Andreas, take take take us through quickly how a clinician is to identify these four phenotypes.
- 17:27SPEAKER_01: Great.
- 17:27SPEAKER_01: So so we knew this was not a feasible, right?
- 17:31SPEAKER_01: So we have built a surrogate biomarker against two of the four phenotypes for hungry brain and hungry gut.
- 17:39SPEAKER_01: So abnormal calories dissociation and abnormal prospinal satiety.
- 17:43SPEAKER_01: We build a genetic biomarker that can tell you whether you have hungry brain or hungry gut.
- 17:49SPEAKER_01: For emotional hunger, they're validated questionnaires.
- 17:52SPEAKER_01: My personal favorite is to measure anxiety because when we look at emotional eating, people are eating for the when they have higher anxiety.
- 18:00SPEAKER_01: But there are other emotional eating questionnaires that are very well validated, such as the three-factor eating questioner.
- 18:06SPEAKER_01: And then for the slow burn, we continue to rely on measuring the rest in energy expenditure as we don't have any alternatives right now or a simple surrogate biomarker.
- 18:15SPEAKER_01: But what I like to take to my patients and to my colleagues, to patients and colleagues, is by just spending time with your patient and having this conversation, phenotype-based conversation or phenotype-tailored conversation, we're already gaining a lot.
- 18:29SPEAKER_01: And if you want to be fully accurate and really get it exactly like we have in our studies, start doing the 10-hour phenotype at MEA, like we do at MEA.
- 18:37SPEAKER_00: Okay.
- 18:38SPEAKER_00: So let me move on now to what I think one of the most exciting areas that really separates out your phenotypic identification, which has been done a lot in other areas, to matching it to outcomes to pharmacotherapy.
- 18:53SPEAKER_00: That is really, I think, that bridge that you are starting in exciting areas.
- 18:57SPEAKER_00: So take us through the pharmacologic response that you're seeing with this, with these phenotypes, because we don't have anything now that predicts response other than put them on a drug and see how they do.
- 19:10SPEAKER_00: Yours is really the first I'm aware of where a clinician can upfront by taking a history and perhaps doing some of these tests, can potentially tailor what medication they're going to do best on.
- 19:21SPEAKER_00: So take us through that.
- 19:23SPEAKER_00: Yeah, absolutely, Dr.
- 19:24SPEAKER_01: Kusher.
- 19:25SPEAKER_01: So, you know, the real fact of what we are doing this is not only to understand obesity, understand the root cause of obesity, but really trying to pair the biology of obesity with each one of the medications.
- 19:39SPEAKER_01: And I understand that many of you have been hearing a lot about like GOP1s, for example.
- 19:43SPEAKER_01: But GOP1s work in a certain way that other medications that are currently in the pipeline or were previously approved work in a different way.
- 19:52SPEAKER_01: So back in 2015, which is where our first paper came out, we started trying to pair this biology of the phenotypes to each one of the medications we have back then, and we have continued to do this in a series of some of them randomized placebo control trials, but of course, pilot studies, NIH-sponsored studies, don't expect to see thousands of patients, right?
- 20:13SPEAKER_01: You can see smaller sample sizes.
- 20:16SPEAKER_01: And now we have also done some real world as well as pragmatic studies.
- 21:03SPEAKER_01: The best responders are those patients with the hungry gut phenotype.
- 21:07SPEAKER_01: So, which is quite interesting.
- 21:09SPEAKER_01: And in the paper that is already in pre-print in gastroenterology, we show that patients who actually are not making enough GOP1 and have a rapid gastric emptying and feel hungry in between meals, when you give them a GOP1 receptor agonist, they are the best responders.
- 21:26SPEAKER_01: And we have shown that already in post hoc analysis of double-blinded randomized trials as well as real-world studies.
- 21:32SPEAKER_01: So that is very interesting news.
- 21:36SPEAKER_01: For patients with hungry brain, we showed in the first study, in a two week study, and then we validated that in 2025 with a one year study, with pentamintopiramate extended release, a medication that was approved in 2012, that these medications help us in those patients who have the hungry brain or this high calories to satiation.
- 21:57SPEAKER_01: So they are the best responders.
- 21:58SPEAKER_01: They lose two times.
- 22:00SPEAKER_01: More weight, whether you are your hungry brain positive or hungry brain negative.
- 22:05SPEAKER_01: For patients with emotional hunger, which we have shown in a uh retrospective studies that patients who have uh emotional eating, they are the better responders to naltrexone blupropyin, another medication that was approved in 2014 for the treatment of obesity, combine naltrexone with blupropine, and uh they do well.
- 22:26SPEAKER_01: And then for the slow burn patients, there's no medication so far, but we have done a series of studies also with studying the diet and lifestyle interventions, and we know these patients with slow burn respond the best to exercise with high intensity interval training plus resistance training.
- 22:44SPEAKER_01: And what I just explained to you, Dr.
- 22:46SPEAKER_01: Kusner, is that is only using existing and FDA-approved medications.
- 22:50SPEAKER_01: I'm super excited how the future is gonna look with the new medications and how we will be able to pair them to each one of the phenotypes.
- 22:56SPEAKER_01: Yeah.
- 22:57SPEAKER_00: I'm gonna get to that in just a minute because these this is a snack on amylin, so we're gonna get that to a moment.
- 23:02SPEAKER_00: But just to recap, if I hear you correctly, is that by doing phenotypic selection, you're more likely you're likely to lose more weight than if you did standard of care um uh um selection.
- 23:17SPEAKER_00: And you mentioned one, which I think it was the hungry gut, where it's a two-fold increase of response.
- 23:23SPEAKER_00: Are you seeing that kind of magnitude with the other phenotypes using your phenotype selected medication twofold or so?
- 23:30SPEAKER_01: Yeah, so we saw the twofold with hungry brain with phenomine topiramate.
- 23:34SPEAKER_01: Uh so and then to put into numbers in the randomized placebo control trial that we did, 52 weeks, one year, we see that patients on pentamine who are hungry brain negative, they're losing around 9% of body weight loss, while those who are hungry brain positive lost 17%.
- 23:52SPEAKER_01: So 9 to 17%, same medication, same dose, double-blinded placebo control trial.
- 23:59SPEAKER_01: With the GOP ones, we don't see the 2x effect.
- 24:02SPEAKER_01: We see a little bit more about a 60% improvement.
- 24:04SPEAKER_01: What we have seen in our studies is that, for example, with SEMA, that is already presented in a meeting, patients who are hungry got negative, lost around 12% at one year, versus 18% if you were hungry, got positive.
- 24:19SPEAKER_01: So a little bit difference in a randomized placebo control trial with Lyra at 16 weeks was only a 16-week study.
- 24:27SPEAKER_01: 3% if you're hungry got negative, 6% if you're hungry got positive.
- 24:33SPEAKER_01: So really separate them a little bit there.
- 24:36SPEAKER_01: So, but it's um what I like to say is your total body weight loss matters, but also percentage of response.
- 24:43SPEAKER_01: And depending on what cutoff we want to use, we can improve about 30% of the response rate to 80% of the response rate.
- 24:51SPEAKER_00: Well, I think I think what you're demonstrating is extremely important because we all are aware of the heterogeneity of response to pharmacotherapy.
- 24:59SPEAKER_00: And we're always scratching our head about how do we get to that variance.
- 25:04SPEAKER_00: We do know that females, at least in the newer medications, lose more weight than males, uh, whether it's estrogen or you know, uh response, uh, as well as changing, you know, different lean body mass and body fat and so forth.
- 25:18SPEAKER_00: In your studies, have you seen females more responsive than males, even by using your phenotypic um designations?
- 25:27SPEAKER_01: Uh yes.
- 25:28SPEAKER_01: So we have seen that women with hungry gut tend to lose even more weight than uh women without the hungry gut.
- 25:35SPEAKER_01: But what is very interesting from our studies is that individuals with hungry brain, uh, when we look at their genetics, it's more common to be males who have the genetics that is drive the hungry brain, even though that doesn't get to be statistically different, is a higher prevalence.
- 25:52SPEAKER_01: And we see that patients with uh who are males who have a hungry brain tend to do better with phenomintopyramid.
- 25:58SPEAKER_01: So it's a very interesting observation that there's something biologically that might be driven.
- 26:04SPEAKER_01: And even though I haven't said this, it's important to say this each one of our energy balance phenotypes are uh are sex specific because sex is the most important biological factor when we talk about energy balance.
- 26:16SPEAKER_01: Of course, you know, we can say men might eat more than women, but it's not simple just because they are height or our muscle mass.
- 26:23SPEAKER_01: There's something else driving this that is driven that sex becomes a biological factor, it needs to take into question.
- 27:14SPEAKER_00: But turning amylen, uh, as well as those, we can even throw gluagon in there because these are the other nutrient-stimulated gut hormones that we are now starting to see as monoagonists, dual agonists, or triagonist.
- 27:25SPEAKER_00: Do you have an anticipation how let's take amylen will play out in your phenotypic uh uh framework?
- 27:34SPEAKER_01: Yeah, absolutely.
- 27:35SPEAKER_01: So um so it's fascinating because when you look at biological driven classification of obesity or certification of obesity, and and pharma and our scientists and colleagues continue to advance the science of obesity understanding, we just need to understand how that molecule or that how that hormone works.
- 27:54SPEAKER_01: So if we look at amylene, you know, scientists like Thomas Lutz, who is an expert in in um in amylene, is one of the world's experts uh coming from from the University of Zurich in Switzerland, he has told us that amylene, this pancreatic hormone, is essential in inducing sasiation.
- 28:18SPEAKER_01: So if we if we know that amylene gets released on the pancreas but very early on during the meal and control that meal size, I can already hypothesize, and I'm gonna repeat that and make a big emphasis, this is a hypothesis because I have no data to show that to prove this, not even in animal models, is a hypothesis that most likely those people with high calories to sciation might not be responding appropriately to our endogenous amylene.
- 28:46SPEAKER_01: And when we give them amylene, they might be super responders.
- 28:51SPEAKER_01: So I can't wait to test that, but right now that's a hypothesis.
- 28:55SPEAKER_00: Thank you, Andreas.
- 28:56SPEAKER_00: You know, before we wrap up, let me add more context to round out our conversation.
- 29:01SPEAKER_00: We walk through four energy balance phenotypes: hungry brain, hungry gut, emotional hunger, and slow burn.
- 29:10SPEAKER_00: I want to widen the lens for a moment because alongside those appetite and energy traits, each patient also carries a metabolic burden profile.
- 29:18SPEAKER_00: Things like hypertension, insulin resistance, and visceral adiposity.
- 29:23SPEAKER_00: Those aren't separate from the phenotype conversation.
- 29:26SPEAKER_00: They actually travel with it.
- 29:28SPEAKER_00: They shape a patient's cardiometabolic risk and increasingly they shape how we should judge whether a therapy is truly helping that individual.
- 29:37SPEAKER_00: Not just how much weight comes off, but what happens to that metabolic burden.
- 29:41SPEAKER_00: Now, turning to amelin, since that's a thread running through this whole series, Dr.
- 29:46SPEAKER_00: Acosta offered hypothesis, that patients with high calories to satiation, so-called hungry brain group, might be the ones who respond best when we restore amylene signaling.
- 29:59SPEAKER_00: You know, we don't yet have data that tests that phenotype hypothesis head on, but the amylene signals coming out of the clinic are worth putting on your radar.
- 30:10SPEAKER_00: CAGRONITIED, a long-acting amylene analog, produced roughly 11 to 12% weight loss on its own over about 16 months.
- 30:19SPEAKER_00: And paired with semaglytide known as CAGRACEMA, mean weight loss reached about 20 to 23% in the phase three redefined program.
- 30:29SPEAKER_00: A newer amylen analog, given as monotherapy called petrolintide, produced around 11% in a phase two trial with tolerability that looked close to placebo, with very few GI side effects we've come to expect.
- 30:46SPEAKER_00: But two signals matter most for a phenotypic lens.
- 30:49SPEAKER_00: First, the response is heterogeneous, clear super responders compared to patients who don't lose much weight at all.
- 30:56SPEAKER_00: And second, in that phase two amylin trial, women lost considerably more weight than men, echoing the sex stratified patterns Dr.
- 31:05SPEAKER_00: Acosta described with our existing agents.
- 31:09SPEAKER_00: These trials also track cardiometricabolic parameters, glucose, hemoglobin A1C, lipids, inflammatory markers like CRP, not just the number on the scale.
- 31:22SPEAKER_00: So the subgroup story for AMLIN is just beginning to be written, and it's exactly the kind of data we should be reaching through to identify phenotypes and a sex-specific lens.
- 31:36SPEAKER_00: So, how should we read the wave of AMLI data that's coming?
- 31:40SPEAKER_00: My suggestion: look past the headline weight loss percentages.
- 31:44SPEAKER_00: Total body weight matters, but on its own it hides the heterogeneity Dr.
- 31:49SPEAKER_00: Acosta and I have been describing.
- 31:51SPEAKER_00: Keep an eye on what's happening to appetite and satiation.
- 31:55SPEAKER_00: What's the drug doing mechanistically?
- 31:58SPEAKER_00: What does the biology predict?
- 32:00SPEAKER_00: How durable, how persistent is the effect over time?
- 32:04SPEAKER_00: Remembering that obesity is a chronic progressive disease.
- 32:07SPEAKER_00: What's happening to those cardiometabolic parameters we just talked about?
- 32:11SPEAKER_00: And who responds, which phenotypes, and which sex?
- 32:15SPEAKER_00: Reading emerging data through that lens rather than through weight loss alone is how we move from one size fits all prescribing toward matching the right biology to the right patient.
- 32:27SPEAKER_00: So, Andreas, let me toss this back to you.
- 32:30SPEAKER_00: What is your take-home message for clinicians who are watching this snack today?
- 32:36SPEAKER_01: Well, I think it's important to understand that physicians to live with understanding that there will be heterogeneity on outcomes.
- 32:43SPEAKER_01: So when people, when our physicians or colleagues are learning about the use of medications, start using them, they need to know the reality.
- 32:50SPEAKER_01: Not every patient is going to respond as average.
- 32:53SPEAKER_01: And of course, there will be super responders and poor responders.
- 32:56SPEAKER_01: Those poor responders are not to be blamed.
- 32:59SPEAKER_01: That's just generating more stigma and obesity.
- 33:02SPEAKER_01: We need to understand that most likely the biology of the poor responders was not the right for that medication.
- 33:08SPEAKER_01: But when we have such a rich toolbox, right, already very rich, and it's going to be even more full of different tools to use with amylene, we use that glucagon type medications.
- 33:19SPEAKER_01: We're going to be even using this GOP1 base, as the GOP1s will be the foundation.
- 33:24SPEAKER_01: And then we can add amylene, we can either add, you know, a stronger GIP, we can add glucagon, and each one might be able to be tailored to the individual phenotypes.
- 33:34SPEAKER_01: And we also need to understand that obesity is a recurrent disease.
- 33:41SPEAKER_01: So not because you once had this phenotype, that doesn't mean that eventually you can actually have more of a dynamic process once you go through these metabolic adaptations, and suddenly something else might pop up.
- 33:53SPEAKER_01: So it's not a one-time and done, you're getting stuck to this medication and that's it.
- 33:57SPEAKER_01: But hey, maybe after you lost weight, maybe now you have more of a hungry brain phenotype that you didn't have before.
- 34:03SPEAKER_01: So genetics play a role, but it's only about 60% of the story.
- 34:08SPEAKER_01: So we need to understand so as obesity experts, as in the trenches, need to think about this dynamic disease that is recurrent, and we need to be very thankful that we have so many tools now to manage it.
- 34:21SPEAKER_00: Thank you.
- 34:21SPEAKER_00: Wise, wise conclusions.
- 34:24SPEAKER_00: Dr.
- 34:25SPEAKER_00: Custom, this has been wonderful.
- 34:26SPEAKER_00: We have to wrap it up.
- 34:27SPEAKER_00: Now I want to thank you so much for your insight and your wonderful description of the work that you're doing.
- 34:32SPEAKER_00: And I think we're all looking forward to more work and more understanding because pharmacotherapy, particularly these nutrient stimulating hormone-based medications, and the first generation, which you mentioned, are here to stay.
- 34:43SPEAKER_00: We need to do a better job.
- 34:45SPEAKER_00: I've certainly enjoyed the conversation.
- 34:47SPEAKER_00: I hope all of you have as well.
- 34:49SPEAKER_00: And thank you to our audience for participating.
- 34:52SPEAKER_00: It is indeed an exciting time to be involved in the care of patients with obesity.
- 34:56SPEAKER_00: To receive CMEC credit, please complete the post test and evaluation.
- 35:02SPEAKER_00: Lastly, don't forget to check out the other three snacks in the series now listed on your screen.
- 35:09SPEAKER_00: Thank you.